32,081 results match your criteria Lymphoma Lymphoblastic


[Cancer immune therapy for the treatment of haematological malignancies].

Ugeskr Laeger 2019 Mar;181(10)

Cancer immune therapy is now used routinely for the treatment of several solid malignancies, albeit just recently having entered the clinic for treatment of haematological malignancies. Several studies demonstrate that cancer immune therapy is a promising treatment modality for the latter. Especially treatment with chimeric antigen receptor T cells for acute lymphoblastic leukaemia and lymphoma is promising. Read More

View Article

Download full-text PDF

Source

PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)-Rationale and Design.

Thromb Haemost 2019 Mar 12. Epub 2019 Mar 12.

Division of Pediatric Hematology/Oncology, Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, United States.

Venous thromboembolic (VTE) complications in children and adolescents with acute lymphoblastic leukaemia (ALL) and T or B cell lymphoblastic lymphoma (T/B cell LL) can result not only in life-threatening acute complications but also contribute to significant long-term sequelae. The PREVAPIX-ALL study is an open-label randomized controlled study comparing outcomes of treatment with prophylactic dose apixaban versus no anticoagulation (standard of care) in children and adolescents with ALL and T/B cell LL receiving standard induction chemotherapy with asparaginase and the presence of a central venous access device. On day 29 of induction, all patients undergo screening imaging with duplex ultrasonography and echocardiography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0039-1679938DOI Listing

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.

J Pharmacokinet Pharmacodyn 2019 Mar 11. Epub 2019 Mar 11.

Pfizer Oncology, Collegeville, PA, USA.

This population pharmacokinetics analysis evaluated the target-mediated drug disposition of inotuzumab ozogamicin (InO) through an empirical time-dependent clearance (CL) term and identified potential covariates that may be important predictors of variability in InO distribution and elimination. This analysis was conducted by pooling data from 2 studies of single-agent InO in patients with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (ALL), 3 studies of single-agent InO, 5 studies of InO plus rituximab (R-InO), and 1 study of R-InO plus chemotherapy in patients with R/R B-cell non-Hodgkin lymphoma (NHL). Pharmacokinetic data included 8361 InO concentration-time observations that were modeled using nonlinear mixed-effects analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10928-018-9614-9DOI Listing

'What are you crying for? I don't even know you' - The experiences of teenagers communicating with their peers when returning to school.

Eur J Oncol Nurs 2019 Apr 24;39:28-34. Epub 2018 Dec 24.

The School of Psychology, The University of Leeds, Leeds, West Yorkshire, England, United Kingdom.

Purpose: Young people (YP) returning to school after a cancer diagnosis and treatment have to decide who has the right to know about their cancer experiences and how to distribute this information to peers. Young people face unique challenges in this area because of their life stage, their need to reintegrate with peers, and their own approach to their disease and treatment. This paper explores the perspectives of young people as they return to school during and after curative cancer treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejon.2018.12.010DOI Listing
April 2019
2 Reads

Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia: Early Diagnosis and New Treatment Strategies.

Anticancer Res 2019 Mar;39(3):1259-1266

Department of Women's and Children's Health, Pediatric Haemato-Oncology, University of Padua, Padua, Italy.

Background/aim: In the last few decades, treatment strategies for acute lymphoblastic leukemia (ALL) have been associated not only with improvement of prognosis, but also with an increasing rate of late complication as osteonecrosis (ON). Herein, the cumulative incidence, risk factors, new conservative therapeutic strategies as hyperbaric oxygen therapy (HBO), and outcome of symptomatic ON were studied in pediatric patients with ALL.

Patients And Methods: Between 2000 and 2017, 495 children and young adolescents with a diagnosis of ALL were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13236DOI Listing
March 2019
1 Read

Association of Promoter Polymorphisms With the Risk of Childhood Leukemia.

Anticancer Res 2019 Mar;39(3):1185-1190

Department of Physiology, China Medical University, Taichung, Taiwan, R.O.C.

Background/aim: The association of matrix metalloproteinase-2 (MMP-2) genotypes with adult leukemia has been reported only once, but never for childhood leukemia. This study aimed to determine the role of MMP-2 promoter -1306 (rs243865) and -735 (rs2285053) genotypes in childhood leukemia risk.

Materials And Methods: This case-control study included 266 patients and 266 age- and gender-matched healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13228DOI Listing

Mechanisms of resistance to CAR T cell therapy.

Nat Rev Clin Oncol 2019 Mar 5. Epub 2019 Mar 5.

Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

The successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas have revolutionized anticancer therapy, providing a potentially curative option for patients who are refractory to standard treatments. These trials resulted in rapid FDA approvals of anti-CD19 CAR T cell products for both ALL and certain types of B cell lymphoma - the first approved gene therapies in the USA. However, growing experience with these agents has revealed that remissions will be brief in a substantial number of patients owing to poor CAR T cell persistence and/or cancer cell resistance resulting from antigen loss or modulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0184-6DOI Listing
March 2019
2 Reads

[The prognostic significance of minimal residual disease detection after first induction treatment in adult acute lymphoblastic leukemia patients treated with autologous stem cell transplantation].

Zhonghua Xue Ye Xue Za Zhi 2019 Feb;40(2):105-110

Department of Lymphoma Center, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin 300020, China.

To investigate the prognostic significance of detection of minimal residual disease after first induction treatment (MRD(1)) in adult acute lymphoblastic leukemia (ALL) patients treated with autologous stem cell transplantation (auto-HSCT). The clinical data of 87 ALL patients who underwent auto-HSCT during February 2006 to April 2017 with MRD(1) detection data by flow cytometry were analyzed retrospectively. The relationship between MRD(1) and relapse and survival of ALL patients after auto-HSCT was studied. Read More

View Article

Download full-text PDF

Source
http://www.hematoline.com/CN121090201902/1117637.htm
Publisher Site
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.02.003DOI Listing
February 2019
6 Reads

Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.

Lancet Haematol 2019 Feb 27. Epub 2019 Feb 27.

Childrens Cancer Group, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Tata Translational Cancer Research Centre, Tata Medical Center, New Town, Kolkata, India. Electronic address:

Background: The ALLR3 trial investigated outcomes of children with B-cell precursor acute lymphoblastic leukaemia who had late bone marrow relapses. We analysed long-term follow-up outcomes of these patients.

Methods: ALLR3 was an open-label randomised clinical trial that recruited children aged 1-18 years with B-cell precursor acute lymphoblastic leukaemia who had late bone marrow relapses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30003-1DOI Listing
February 2019
2 Reads

Cellular immunotherapy for acute myeloid leukemia: How specific should it be?

Blood Rev 2019 Feb 23. Epub 2019 Feb 23.

Toronto General Research Institute, University Health Network, 2-207 101 College St., Toronto, Ontario M5G 1L7, Canada; Department of Immunology, University of Toronto, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Electronic address:

Significant improvements in the survival of patients with hematological cancers following hematopoietic stem cell transplantation provide evidence supporting the potency of immune cell-mediated anti-leukemic effects. Studies focusing on immune cell-based cancer therapies have made significant breakthroughs in the last few years. Adoptive cellular therapy (ACT), and chimeric antigen receptor (CAR) T cell therapy, in particular, has significantly increased the survival of patients with B cell acute lymphoblastic leukemia and aggressive B cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.02.001DOI Listing
February 2019
2 Reads

Pediatric Malignant Mediastinal Masses.

J Coll Physicians Surg Pak 2019 Mar;29(3):258-262

Department of Pediatric Hematology-Oncology and Bone Marrow Transplant, The Children's Hospital and Institute of Child Health, Lahore, Pakistan.

Objective: To describe the clinical spectrum and outcome-associated variables of pediatric malignant mediastinal masses in a resource-limited setting.

Study Design: Descriptive study.

Place And Duration Of Study: Department of Pediatric Hematology-Oncology, The Children's Hospital, Lahore, from October 2016 to November 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.29271/jcpsp.2019.03.258DOI Listing
March 2019
2 Reads

Prognostic miRNA classifiers in t cell acute lymphoblastic leukemia: Study protocol for a systematic review and meta-analysis of observational clinical studies.

Medicine (Baltimore) 2019 Mar;98(9):e14569

College of Health and Human Sciences, Charles Darwin University, Casuarina, Northern Territory, Australia.

Background: The prognostic value of microRNA (miRNA) expression in T-cell acute lymphoblastic leukemia (T-ALL) has generated significant research interest in recent years. However, most diagnostic and prognostic studies with regards to miRNA expression have been focused on combined B cell and T cell lymphoblastic leukemia. There are very few studies reporting the prognostic effects of miRNA expression on T-ALL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014569DOI Listing

Sex ratio among childhood cancers by single year of age.

Pediatr Blood Cancer 2019 Feb 28:e27620. Epub 2019 Feb 28.

Division of Epidemiology and Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.

Background: The male excess in childhood cancer incidence is well-established; however, the underlying biologic mechanisms remain unknown. Examining the association between male sex and childhood cancer by single year of age and tumor type may highlight important periods of risk such as variation in growth and hormonal changes, which will inform etiologic hypotheses.

Methods: Using data from the Surveillance, Epidemiology, and End Results (SEER) 18 registries (2000-2015), incidence rate ratios (IRR) and 95% confidence intervals (95% CI) were estimated as the measure of association between male sex and childhood cancer by single year of age (0-19). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27620DOI Listing
February 2019
1 Read

Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities.

Br J Haematol 2019 Feb 27. Epub 2019 Feb 27.

Pediatric Hematology and Oncology, University of California, San Francisco, CA, USA.

Lymphoblastic lymphoma (LBL) is the second most common type of Non-Hodgkin Lymphoma (NHL) in childhood and adolescence, accounting for 25-35% of all cases. The majority, 70-80%, is of T-lymphoblastic origin while 20-25% arise from B lymphoblasts. With current therapy, the event-free and overall survivals for paediatric LBL patients now exceeds 80%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15793DOI Listing
February 2019
1 Read

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells.

Blood 2019 Feb 26. Epub 2019 Feb 26.

Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, United States;

Chimeric antigen receptor (CAR) T-cells have emerged as a promising class of cell-based immunotherapy in refractory malignancies. Neurotoxicity represents a common and potentially life-threatening adverse effect of CAR T-cells, and clinical experience is limited. Here, we describe the clinical presentation and management of 25 adult patients who presented with neurotoxic syndromes after CAR T-cell therapy at the Massachusetts General Hospital. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-12
Publisher Site
http://dx.doi.org/10.1182/blood-2018-12-893396DOI Listing
February 2019
4 Reads
10.452 Impact Factor

S194-P-FADD as a marker of aggressiveness and poor prognosis in human T-cell lymphoblastic lymphoma.

Carcinogenesis 2019 Feb 26. Epub 2019 Feb 26.

Departamento de Biología, Universidad Autónoma de Madrid, Madrid, Spain.

T-cell lymphoblastic lymphoma is a haematological disease with an urgent need for reliable prognostic biomarkers that allow therapeutic stratification and dose adjustment. The scarcity of human samples is responsible for the delayed progress in the study and the clinical management of this disease, especially compared to T-cell acute lymphoblastic leukaemia, its leukemic counterpart. In the present work, we have determined by immunohistochemistry that S194-P-FADD protein is significantly reduced in a cohort of 22 samples from human T-cell lymphoblastic lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgz041DOI Listing
February 2019
1 Read

Stage at diagnosis for children with blood cancers in Australia: Application of the Toronto Paediatric Cancer Stage Guidelines in a population-based national childhood cancer registry.

Pediatr Blood Cancer 2019 Feb 25:e27683. Epub 2019 Feb 25.

Cancer Council Queensland, Brisbane, Queensland, Australia.

Background: Information on stage at diagnosis for childhood blood cancers is essential for surveillance but is not available on a population basis in most countries. Our aim was to apply the internationally endorsed Toronto Paediatric Cancer Stage Guidelines to children (<15 years) with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL) and to assess differences in survival by stage at diagnosis.

Procedure: Stage was defined by extent of involvement of the central nervous system (CNS) for ALL and AML and using the Ann Arbor and St Jude-Murphy systems for HL and NHL, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27683DOI Listing
February 2019
1 Read
2.562 Impact Factor

Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor T-cell therapy.

Expert Rev Hematol 2019 Feb 22. Epub 2019 Feb 22.

a Division of Medical Oncology, Department of Internal Medicine , University of Washington School of Medicine , Seattle , WA , USA.

Introduction: Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated remarkable anti-tumor activity in B-cell malignancies and is under investigation in other hematologic malignancies and solid tumors. While highly efficacious, post-infusion T cell activity often results in massive cytokine release precipitating cytokine release syndrome (CRS), the signature toxicity of CAR T cells. This toxicity is characterized by systemic immune activation resulting in fever, hypotension, respiratory insufficiency and capillary leak. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1585238DOI Listing
February 2019
3 Reads

Utility of the number needed to treat in paediatric haematological cancer randomised controlled treatment trials: a systematic review.

BMJ Open 2019 Feb 20;9(2):e022839. Epub 2019 Feb 20.

School Of Nursing, University of British Columbia, Vancouver, British Columbia, Canada.

Objectives: The primary objective was to assess the utility of the number needed to treat (NNT) to inform decision-making in the context of paediatric oncology and to calculate the NNT in all superiority, parallel, paediatric haematological cancer, randomised controlled trials (RCTs), with a comparison to the threshold NNT as a measure of clinical significance.

Design: Systematic review DATA SOURCES: MEDLINE, EMBASE and the Cochrane Childhood Cancer Group Specialized Register through CENTRAL from inception to August 2018.

Eligibility Criteria For Selecting Studies: Superiority, parallel RCTs of haematological malignancy treatments in paediatric patients that assessed an outcome related to survival, relapse or remission; reported a sample size calculation with a delta value to allow for calculation of the threshold NNT, and that included parameters required to calculate the NNT and associated CI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2018-022839DOI Listing
February 2019
1 Read

Predictable and Unusual Adverse Effects of Immunosuppression in Pediatric Liver Transplant Patients.

Exp Clin Transplant 2019 01;17(Suppl 1):230-233

From the Department of Pediatric Gastroenterology,Gazi University Faculty of Medicine, Ankara, Turkey.

Objectives: Our aim was to determine potentially adverse effects of immunosuppressive protocols after liver transplantation in children.

Materials And Methods: The medical records of 60 children who underwent liver transplant retrospectively analyzed. Corticosteroid, tacrolimus, and mycophenolate mofetil were the primary immunosuppressive agents used in our center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6002/ect.MESOT2018.P81DOI Listing
January 2019
3 Reads

A Case of Renal Involvement in B Lymphoblastic Lymphoma Leukemia.

Clin Lab 2019 Jan;65(1)

Background: Renal involvement is rare in B lymphoblastic lymphoma (B-LBL). The authors describe a rare case of renal involvement in a 21-year-old male patient with B lymphoblastic lymphoma leukemia, presenting with severe lactic acidosis.

Methods: Hematologic investigation, bone marrow aspirate and biopsy, cytogenetic analysis and renal biopsy were performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7754/Clin.Lab.2018.180726DOI Listing
January 2019
1 Read
1.084 Impact Factor

Incidence of infections after therapy completion in children with acute lymphoblastic leukemia or acute myeloid leukemia: a systematic review of the literature.

Leuk Lymphoma 2019 Feb 18:1-11. Epub 2019 Feb 18.

a Division of Haematology/Oncology, Department of Paediatrics , The Hospital for Sick Children , Toronto , Canada.

Infections are a common complication of treatment for pediatric acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). Less is known about infections occurring after treatment. We performed a systematic review of the literature to assess the incidence of infections after therapy completion in children and young adults with ALL or AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1573369DOI Listing
February 2019
1 Read

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia.

J Hematol Oncol 2019 Feb 14;12(1):17. Epub 2019 Feb 14.

The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 127 Dongming Road, Zhengzhou, 450008, China.

The current treatment for pediatric acute lymphoblastic leukemia (ALL) is highly successful with high cure rate. However, the treatment of adult ALL remains a challenge, particularly for refractory and/or relapsed (R/R) ALL. The advent of new targeted agents, blinatumomab, inotuzumab ozogamycin, and chimeric antigen receptor (CAR) T cells, are changing the treatment paradigm for ALL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-019-0705-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376657PMC
February 2019
1 Read
4.812 Impact Factor

Allogeneic blood transfusion in 163 children with acute lymphocytic leukemia (a STROBE-compliant article).

Medicine (Baltimore) 2019 Feb;98(7):e14518

Department of Pediatrics, the First Affiliated Hospital of Zhengzhou University.

Little research has been done about the effects of allogeneic blood transfusion (ABT) on the recurrence and prognosis in the cases with childhood acute lymphocytic leukemia (cALL). In order to provide a basis for clinical safe blood transfusion, the data of 163 cases with cALL were retrospectively analyzed to explore the issue.The data of 163 cases with cALL between 2006 and 2011 were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014518DOI Listing
February 2019

Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.

Hematology 2019 Dec;24(1):337-348

n Ospedale dell'Angelo , Mestre-Venezia , Italy.

Objectives: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10 Methods: Study population was from ALL study groups in Europe managed in national study protocols 2000-2014. MRD was measured by polymerase chain reaction or flow cytometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1567654DOI Listing
December 2019
2 Reads

Downregulation of specific FBXW7 isoforms with differential effects in T-cell lymphoblastic lymphoma.

Oncogene 2019 Feb 11. Epub 2019 Feb 11.

Centro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.

FBXW7 is a driver gene in T-cell lymphoblastic neoplasia acting through proteasome degradation of key proto-oncogenes. FBXW7 encodes three isoforms, α, β and γ, which differ only in the N-terminus. In this work, massive sequencing revealed significant downregulation of FBXW7 in a panel of primary T-cell lymphoblastic lymphomas characterised by the absence of mutations in its sequence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-019-0746-1DOI Listing
February 2019
3 Reads

CRISPR/Cas9-based genome editing in the Era of CAR T cell immunotherapy.

Hum Vaccin Immunother 2019 Feb 8. Epub 2019 Feb 8.

a Center for Cellular Immunotherapies, Abramson Cancer Center , University of Pennsylvania , Philadelphia , PA , USA.

The advent of engineered T cells as a form of immunotherapy marks the beginning of a new era in medicine, providing a transformative way to combat complex diseases such as cancer. Following FDA approval of CAR T cells directed against the CD19 protein for the treatment of acute lymphoblastic leukemia and diffuse large B cell lymphoma, CAR T cells are poised to enter mainstream oncology. Despite this success, a number of patients are unable to receive this therapy due to inadequate T cell numbers or rapid disease progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21645515.2019.1571893DOI Listing
February 2019
1 Read

Pediatric non-Hodgkin lymphoma: Characteristics, stratification, and treatment at a single institute in Thailand.

Pediatr Int 2019 Jan;61(1):49-57

Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Background: In the modern era of chemotherapy, the outcome of pediatric non-Hodgkin lymphoma (NHL) continues to improve internationally. Limited data such as information on epidemiology and survival, however, are available in Asian countries.

Methods: Children (≤15 years old) diagnosed with histologically proven NHL from 1998 to 2014 were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ped.13739DOI Listing
January 2019
1 Read

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity than SAR3419 in CD19-positive lymphoma and leukemia models.

Haematologica 2019 Feb 7. Epub 2019 Feb 7.

Università della Svizzera italiana, Institute of Oncology Research;

Antibody-drug conjugates (ADCs) are a novel way to deliver potent cytotoxic compounds to cells expressing a specific antigen. Four ADCs targeting CD19, including SAR3419 (coltuximab ravtansine), have entered clinical development. Here, we present huB4-DGN462, a novel ADC based on the SAR3419 anti-CD19 antibody linked via sulfo-SPDB to the potent DNA-alkylating agent DGN462. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.211011DOI Listing
February 2019
1 Read

Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives.

Br J Haematol 2019 Feb 6. Epub 2019 Feb 6.

Division of Paediatric Haemato-Oncology, Princess Maxima Centre for Paediatric Oncology, Utrecht, The Netherlands.

The 6th International Symposium on Childhood, Adolescent and Young Adult (CAYA) Non-Hodgkin Lymphoma (NHL) was held in Rotterdam, Netherlands, 26-29 September, 2018. This summary manuscript is a perspective on the presentations from the plenary scientific sessions, including wellness and survivorship, B-cell NHL, AYA lymphoma, translational NHL biology, lymphoma immunology, bone marrow transplantation and cell therapy, T/Natural Killer cell lymphoma, anaplastic large cell lymphoma, lymphoblastic lymphoma, novel lymphoma therapeutics and Hodgkin lymphoma. The symposium was attended by over 260 registrants from 42 different countries and included young, middle and senior investigators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15764DOI Listing
February 2019
1 Read

Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.

Acta Haematol 2019 6;141(2):119-127. Epub 2019 Feb 6.

Department of Pediatric Hematology-Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.

Background: The WHO defined myeloid and lymphoid neoplasms (MLN) with eosinophilia associated with PDGFRB, PDGFRA, FGFR1 rearrangements as a new entity in 2016. PDGFRB-rearranged MLN sensitive to imatinib were described in adult patients. We report the first pediatric patient with PDGFRB-rearranged myeloproliferative disorder associated with T-lymphoblastic lymphoma bearing the t(5; 14)(q33;q32) translocation who was successfully treated with imatinib only. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495687DOI Listing
February 2019
7 Reads

B-cell lymphoblastic leukemia/lymphoma in infants: Report of two cases on the face.

J Dermatol 2019 Feb 5. Epub 2019 Feb 5.

Department of Dermatology, Kansai Medical University Medical Center, Osaka, Japan.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/1346-8138.14
Publisher Site
http://dx.doi.org/10.1111/1346-8138.14799DOI Listing
February 2019
3 Reads

The frequency of NOTCH1 variants in T-acute lymphoblastic leukemia/lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma among Jordanian patients.

Ann Diagn Pathol 2019 Jan 24;39:53-58. Epub 2019 Jan 24.

Department of Physiology and Biochemistry, School of Medicine, The University of Jordan, Amman, Jordan. Electronic address:

The transmembrane receptor NOTCH1 is thought to be associated with the development and progression of T-acute lymphoblastic leukemia (T-ALL)/T-lymphoblastic lymphoma (T-LBL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). The current study aimed to characterize NOTCH1 expression and elucidate the variants in the functional PEST domain of the receptor in T-ALL/LBL and CLL/SLL. The nuclear expression of NOTCH1 protein was detected in 25% and 5% of cases of T-ALL/LBL and CLL/SLL, respectively, whereas cytoplasmic expression was detected in 33. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2019.01.004DOI Listing
January 2019
1 Read
1.112 Impact Factor

Understanding the evolutionary trend of intrinsically structural disorders in cancer relevant proteins as probed by Shannon entropy scoring and structure network analysis.

BMC Bioinformatics 2019 Feb 4;19(Suppl 13):549. Epub 2019 Feb 4.

Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, Massachusetts, 02138, USA.

Background: Malignant diseases have become a threat for health care system. A panoply of biological processes is involved as the cause of these diseases. In order to unveil the mechanistic details of these diseased states, we analyzed protein families relevant to these diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12859-018-2552-0DOI Listing
February 2019
1 Read
2.576 Impact Factor

Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?

Curr Oncol Rep 2019 Feb 4;21(2):17. Epub 2019 Feb 4.

Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga No. 15, Belisario Dominguez Sección XVI, Tlalpan, 14080, Mexico City, Mexico.

Purpose Of Review: The purpose of this review is to discuss the current recommendations for the use of bispecific antibodies (bsAb) in hematologic malignancies and explore the future in this field.

Recent Findings: Bispecific antibodies are molecules able to target two different antigen-binding sites: one towards a tumor antigen and another to activate a cytotoxic cell. Phase II/III trials on blinatumomab for acute lymphoblastic leukemia (ALL) have demonstrated its efficacy for treating minimal residual disease (MRD+) and relapsed refractory (r/r) Philadelphia positive (Ph+) and negative (Ph-) ALL in adults and children. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0759-5
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0759-5DOI Listing
February 2019
10 Reads

Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.

Leuk Lymphoma 2019 Feb 4:1-8. Epub 2019 Feb 4.

a Department of Hematology, Jiangsu Institute of Hematology , The First Affiliated Hospital of Soochow University , Suzhou , China.

Patients with relapsed or refractory E2A-PBX1 positive acute B lymphoblastic leukemia (B-ALL) receiving anti-CD19 chimeric antigen receptor T cells (CAR-T) were retrospectively assessed to evaluate the efficacy and safety of disease burden on outcomes and to identify predictive variables. Of the three case patients, case 1 relapsed after hematopoietic stem cell transplantation. After being treated with anti-CD19 CAR-T, the patient showed minimal residual disease (MRD), and his fusion genes turned negative. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1533127DOI Listing
February 2019
1 Read

Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells.

Front Immunol 2018 18;9:3180. Epub 2019 Jan 18.

Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, India.

Lymphocytes especially autologous T cells have been used for the treatment of numerous indications including cancers, autoimmune disorders and infectious diseases. Very recently, FDA approved Chimeric Antigen Receptor T cells (CAR T cells) therapy for relapse and refractory CD19+ B cell acute lymphoblastic leukemia (r/r B-ALL) and r/r diffuse large B cell lymphoma (r/r DLBCL) upon their remarkable success in multiple Phase I-II clinical trials. While CAR T cells are considered as major breakthrough in the field of cancer immunotherapy, the regulation of CAR T cells remains poorly understood. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2018.03180
Publisher Site
http://dx.doi.org/10.3389/fimmu.2018.03180DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345708PMC
January 2019
6 Reads

Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory.

Genes Chromosomes Cancer 2019 Feb 1. Epub 2019 Feb 1.

Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

The MLLT10 (formerly AF10) gene is the fourth most common KMT2A fusion partner across all acute leukemias and requires at least three breaks to form an in-frame KMT2A/MLLT10 fusion due to the opposite orientation of each gene. A 10-year retrospective review was performed to identify individuals from all age groups that harbor KMT2A/MLLT10 fusion obtained by our KMT2A/MLLT10 dual-color dual-fusion fluorescence in situ hybridization (D-FISH) assay. Of the 60 unique individuals identified, 31 were male and 29 were female (M:F ratio, 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22741DOI Listing
February 2019
1 Read

Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia.

Br J Haematol 2019 Jan 31. Epub 2019 Jan 31.

Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany.

Improvement of survival in lymphocytic leukaemia has been accompanied by the occurrence of second primary cancer (SPCs). Based on Swedish Family Cancer Database, we applied bi-directional analyses in which relative risks (RRs) were calculated for any SPCs in patients with chronic lymphocytic leukaemia (CLL), acute lymphoblastic leukaemia (ALL) and hairy cell leukaemia (HCL) and the risks of these leukaemias as SPCs. After CLL, RRs were significant for 20 SPCs, and high for skin squamous cell cancer (24·58 for in situ and 7·63 for invasive), Merkel cell carcinoma (14·36), Hodgkin lymphoma (7·16) and Kaposi sarcoma (6·76). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15777DOI Listing
January 2019
2 Reads

Cyclophosphamide for the treatment of acute lymphoblastic leukemia: A protocol for systematic review.

Medicine (Baltimore) 2019 Feb;98(5):e14293

Department of Hematology.

Background: Previous clinical trials have reported that cyclophosphamide can be used for the treatment of acute lymphoblastic leukemia (ALL). However, its efficacy is still unclear. In this systematic review study, we aim to evaluate its efficacy and safety for ALL. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005792-201902010-0004
Publisher Site
http://dx.doi.org/10.1097/MD.0000000000014293DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380740PMC
February 2019
9 Reads

Aerobic physical exercise for adult patients with haematological malignancies.

Cochrane Database Syst Rev 2019 01 31;1:CD009075. Epub 2019 Jan 31.

Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, Germany.

Background: Although people with haematological malignancies have to endure long phases of therapy and immobility, which is known to diminish their physical performance level, the advice to rest and avoid intensive exercises is still common practice. This recommendation is partly due to the severe anaemia and thrombocytopenia from which many patients suffer. The inability to perform activities of daily living restricts them, diminishes their quality of life and can influence medical therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD009075.pub3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354325PMC
January 2019
2 Reads

Current development of chimeric antigen receptor T-cell therapy.

Stem Cell Investig 2018 3;5:44. Epub 2018 Dec 3.

Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.

Chimeric antigen receptor (CAR) T-cell therapy has achieved great success in recent years, with encouraging complete remission rate and long-term durability of response, especially in advanced B-cell malignancies. With the approval of tisagenlecleucel and axi-cel by FDA to treat refractory/relapsed acute lymphoblastic leukemia and non-Hodgkin lymphoma, our understanding of CAR T cells has been progressing rapidly. In this review, we discussed the designs of CAR T cells, factors affecting response, adverse effects, as well as application beyond B-cell malignancies. Read More

View Article

Download full-text PDF

Source
http://sci.amegroups.com/article/view/22694/html
Publisher Site
http://dx.doi.org/10.21037/sci.2018.11.05DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327156PMC
December 2018
16 Reads

Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia.

Oncotarget 2018 Dec 28;9(102):37753-37765. Epub 2018 Dec 28.

Department of Oncological Sciences, Icahn School of Medicine, New York 10029, NY, USA.

Overexpression and constitutive activation of CYCLIN D1 and Casein Kinase 2 are common features of many hematologic malignancies, including mantle cell lymphoma (MCL) and leukemias such as T-cell acute lymphoblastic leukemia (T-ALL). Although both CK2 and CDK4 inhibitors have shown promising results against these tumor types, none of these agents have achieved objective responses in the clinic as monotherapies. Because both proteins play key roles in these and other hematological malignancies, we have analyzed the therapeutic potential of ON108110, a novel dual specificity ATP-competitive inhibitor of protein kinase CK2 as well as CDK4/6 in MCL and T-ALL. Read More

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/26514
Publisher Site
http://dx.doi.org/10.18632/oncotarget.26514DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340882PMC
December 2018
7 Reads

Chronic fatigue and associated factors among long-term survivors of cancers in young adulthood.

Acta Oncol 2019 Jan 30:1-10. Epub 2019 Jan 30.

a National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology , Oslo University Hospital , Oslo , Norway.

Background: Chronic fatigue (CF) is scarcely explored among young adult cancer survivors (YACSs), and more knowledge is needed to develop targeted interventions for YACSs with CF. The present study aimed to investigate the prevalence of CF and associated factors in YACSs. Also, the change of fatigue with time was explored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2018.1557344DOI Listing
January 2019
1 Read

The role of adiponectin, LEPTIN, and ghrelin in the progress and prognosis of childhood acute lymphoblastic leukemia.

Leuk Lymphoma 2019 Jan 30:1-12. Epub 2019 Jan 30.

a First Department of Pediatrics , National and Kapodistrian University of Athens, Choremeio Research Laboratory , Athens , Greece.

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Dysregulation of adipokine pathways is implicated in the carcinogenesis and ALL. The aim of this study is to present the most recent data available regarding the role of leptin, adiponectin and ghrelin in the pathogenesis and prognosis of ALL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1569230DOI Listing
January 2019
2 Reads

Feline Lymphoma and a High Correlation with Feline Leukaemia Virus Infection in Brazil.

J Comp Pathol 2019 Jan 29;166:20-28. Epub 2018 Nov 29.

Laboratory of Animal Pathology, Agroveterinary Sciences Center, Brazil. Electronic address:

Lymphoma is the most important haemopoietic tumour in cats and has been associated with feline leukaemia virus (FeLV) infection. In Brazil, no studies have established a correlation between FeLV infection and lymphoma. The aim of this study was to characterize lymphomas arising in cats in Brazil anatomically and microscopically, and to correlate these data with FeLV infection as determined by immunohistochemistry for the FeLV gp70 antigen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcpa.2018.10.171DOI Listing
January 2019
1 Read